达雷妥尤单抗治疗多发性骨髓瘤患者期间的巨细胞病毒和爱泼斯坦-巴尔病毒感染
Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma.
作者信息
Li Shuchan, Zheng Gaofeng, He Jingsong, Wu Wenjun, Chen Qingxiao, Yang Yang, He Donghua, Zhao Yi, Han Xiaoyan, Cai Zhen
机构信息
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
出版信息
Leuk Lymphoma. 2023 Apr;64(4):835-845. doi: 10.1080/10428194.2023.2172982. Epub 2023 Feb 3.
ABSTRACTSWe explored the incidence of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections in 131 patients with multiple myeloma (MM), 53 of whom received daratumumab (Dara) treatments. The Dara group had more RRMM patients than the group without Dara. CMV infection was significantly more common in patients treated with Dara (16.98%) than in patients treated with regimens without Dara (2.56%). During Dara treatments, 24.53% of patients developed CMV and/or EBV infections. Patients who developed infections had significantly lower levels of albumin and lymphocytes in their peripheral blood. The median time from the first Dara infusion to infection was 27 days. We observed NK cell depletion and T cell expansion during Dara-treatment. Patients with CMV and/or EBV infections had significantly lower numbers of NK cells, total T cells, and CD8 + T cells at 1 month, and lower numbers of CD8 + T cells at 2 months after the first Dara infusion than those without infections.
摘要
我们探讨了131例多发性骨髓瘤（MM）患者中爱泼斯坦-巴尔病毒（EBV）和巨细胞病毒（CMV）感染的发生率，其中53例接受了达雷妥尤单抗（Dara）治疗。Dara组的复发/难治性MM（RRMM）患者比未使用Dara的组更多。CMV感染在接受Dara治疗的患者中（16.98%）比接受不含Dara方案治疗的患者（2.56%）明显更常见。在Dara治疗期间，24.53%的患者发生了CMV和/或EBV感染。发生感染的患者外周血白蛋白和淋巴细胞水平显著较低。从首次输注Dara到感染的中位时间为27天。我们在Dara治疗期间观察到自然杀伤（NK）细胞耗竭和T细胞扩增。与未感染的患者相比，发生CMV和/或EBV感染的患者在首次输注Dara后1个月时NK细胞、总T细胞和CD8⁺T细胞数量显著减少，在2个月时CD8⁺T细胞数量减少。
Zotero 插件